TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat ...
Recent research highlights an approach in cancer therapy with small molecule drugs targeting immune checkpoints. These innovative drugs overcome the limitations of antibody-based inhibitors, such as ...
REHOVOT, Israel, Oct. 31, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and ...
SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...
Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback